C. difficile 위험도


Anaerobic infectionC. difficile infectionTrichomoniasisAmebic dysenteryAmebic liver abscess7.5 mg/kg IV/PO q6h x7-10d (max 4 g/d)500 mg IV/PO q8h x10-14d2 g PO #1-2 x1d 250 mg PO q8h x7d750 mg IV/PO q8h x5-10d500-750 mg IV/PO q8h x5-10d

AmebiasisSafety and efficacy in pediatric patients have not been established, except for treatment of amebiasis35-50 mg/kg IV/PO #3 x10d

Mild or moderate hepatic impairmentSevere hepatic impairmentNo dosage adjustment250 mg IV q12h

HD7.5 mg/kg q12h (give one of the dialysis day doses AD) OR consider supplement dose following HD, if administration cannot be separated from the dialysis session

General Information

Suspected or confirmed anaerobic infections including:

  • Intra-abdominal

  • Biliary

  • Central nervous system

  • Clostridium difficile

  • Giardia

  • Pelvic infections

Also used in:

  • Crohn's disease

  • Bacterial vaginosis

  • Hepatic encephalopathy

Black Box Warning: Metronidazole has been shown to be carcinogenic in mice and rats. Its use should be reserved only for conditions for which it is approved.

Assess for peripheral/optic neuropathy with prolonged therapy (>6 weeks) or if symptoms develop.


  • Nausea

  • Diarrhea

  • Abnormal taste in mouth

  • Headache

  • Dizziness

  • Candida infection of genital region

  • Vaginal discharge/irritation

  • Vaginitis


  • Stevens-Johnson syndrome

  • Toxic epidermal necrolysis

  • Leukopenia

  • Hepatic failure (acute)

  • Hepatotoxicity

  • Aseptic meningitis

  • Encephalopathy

  • Peripheral neuropathy

  • Seizure

  • Disorder of optic nerve

  • Ototoxicity

  • Hemolytic uremic syndrome

  • Ethanol:Disulfiram-like reaction

Increases levels of:

  • Cyclosporine

  • Lithium

  • Warfarin

  • Phenobarbital

  • Phenytoin

Antimicrobial class: Nitroimidazole

Pregnancy category: B

Average serum half life: 10 hours

Biliary penetration: Therapeutic

CSF penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Poor

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.